Mir-135a enhances cellular proliferation through post-transcriptionally regulating PHLPP2 and FOXO1 in human bladder cancer

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Mao, Xiao Peng ^a   Zhang, Luo Sheng ^b   Huang, Bin ^a   Zhou, Shi Ying ^a   Liao, Jun ^a   Chen, Ling Wu ^b   Qiu, Shao Peng ^a   Chen, Jun Xing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b PLA458 Hospital   (China)

Author keywords

Bladder cancer; FOXO1; miR 135a; PHLPP2; Proliferation

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MICRORNA; MICRORNA 135A; PROTEIN P21; PROTEIN P27; PROTEIN PHLPP2; REGULATOR PROTEIN; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; MIRN135 MICRORNA, HUMAN; PHLPP2 PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING; BIOLOGICAL MODEL; BLADDER TUMOR; CELL CYCLE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEIN PHOSPHATASES; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 84928233684     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0438-8     Document Type: Article

References (45)

1. Griffiths TR, Action on Bladder C. Current perspectives in bladder cancer management. Int J Clin Pract. 2013;67:435-48.
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-93.
3. Crawford JM. The origins of bladder cancer. Lab Invest. 2008;88:686-93.
4. Micheli A, Francisci S, Krogh V, Rossi AG, Crosignani P. Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL working group. Tumori. 1999;85:309-69.
5. Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18:13-24.
6. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25:917-31.
7. Brognard J, Newton AC. PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab. 2008;19:223-30.
8. Calnan DR, Brunet A. The FoxO code. Oncogene. 2008;27:2276-88.
9. Huang H, Tindall DJ. FOXO factors: a matter of life and death. Future Oncol. 2006;2:83-9.
10. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N. FOXO forkhead transcription factors induce G (2)-M checkpoint in response to oxidative stress. J Biol Chem. 2002;277:26729-32.
11. Arden KC. FoxOs in tumor suppression and stem cell maintenance. Cell. 2007;128:235-7.
12. Xie L, Ushmorov A, Leithauser F, Guan H, Steidl C, Farbinger J, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119:3503-11.
13. Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol. 2005;170:903-12.
14. Dong XY, Chen C, Sun X, Guo P, Vessella RL, Wang RX, et al. FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res. 2006;66:6998-7006.
15. Ronald D, Gary G. FOXO genes act in vivo as tumor suppressors. Canc Biol Ther. 2007;6:132-3.
16. Xi JJ. MicroRNAs in cancer. Cancer Treat Res. 2013;158:119-37.
17. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
18. Mlcochova H, Hezova R, Stanik M, Slaby O. Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol. 2014;32:41. e41-49.
19. Rosenberg E, Baniel J, Spector Y, Faerman A, Meiri E, Aharonov R, et al. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int. 2013;112:1027-34.
20. Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.
21. Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441:976-81.
22. Jiang QQ, Liu B, Yuan T. MicroRNA-16 inhibits bladder cancer proliferation by targeting Cyclin D1. Asian Pac J Cancer Prev. 2013;14:4127-30.
23. Guo Y, Liu H, Zhang H, Shang C, Song Y. miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. Oncol Letters. 2012;4:561-5.
24. Xu X, Li S, Lin Y, Chen H, Hu Z, Mao Y, et al. MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1. J Transl Med. 2013;11:276.
25. Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, et al. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One. 2012;7:e52280.
26. Zaravinos A, Radojicic J, Lambrou GI, Volanis D, Delakas D, Stathopoulos EN, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol. 2012;188:615-23.
27. Flieger A, Golka K, Schulze H, Follmann W. Primary cultures of human urothelial cells for genotoxicity testing. J Toxicol Environ Health A. 2008;71:930-5.
28. Rahman Z, Reedy EA, Heatfield BM. Isolation and primary culture of urothelial cells from normal human bladder. Urol Res. 1987;15:315-20.
29. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002;22:2111-23.
30. Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, et al. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 2013;36:62-8.
31. Majid S, Dar AA, Saini S, Deng G, Chang I, Greene K, et al. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer. PLoS One. 2013;8:e67686.
32. Liu S, Guo W, Shi J, Li N, Yu X, Xue J, et al. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol. 2012;56:389-96.
33. Cheng M, Yang L, Yang R, Yang X, Deng J, Yu B, et al. A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression. Carcinogenesis. 2013;34:2292-9.
34. Yamada Y, Hidaka H, Seki N, Yoshino H, Yamasaki T, Itesako T, et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma. Cancer Sci. 2013;104:304-12.
35. Zhou W, Li X, Liu F, Xiao Z, He M, Shen S, et al. MiR-135a promotes growth and invasion of colorectal cancer via metastasis suppressor 1 in vitro. Acta Biochim Biophys Sin. 2012;44:838-46.
36. Wu H, Huang M, Cao P, Wang T, Shu Y, Liu P. MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation. Cancer Biol Ther. 2012;13:281-8.
37. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008;68:5795-802.
38. Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, et al. miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 2012;12:111.
39. Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2009;28:994-1004.
40. Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013;73:5402-15.
41. Mei Z, He Y, Feng J, Shi J, Du Y, Qian L, et al. MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2. FEBS Lett. 2014;588:3055-61.
42. Fendler A, Jung M, Stephan C, Erbersdobler A, Jung K, Yousef GM. The antiapoptotic function of miR-96 in prostate cancer by inhibition of FOXO1. PLoS One. 2013;8:e80807.
43. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci U S A. 2004;101:13613-7.
44. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci U S A. 2003;100:11285-90.
45. Fatrai S, Elghazi L, Balcazar N, Cras-Meneur C, Krits I, Kiyokawa H, et al. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes. 2006;55:318-25.